# The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

> **NCT04053972** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 377 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04053972
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 377 (ESTIMATED)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053972, "The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04053972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*